ROS-responsive nanoparticle delivery of ferroptosis inhibitor prodrug to facilitate mesenchymal stem cell-mediated spinal cord injury repair
Source abstract
Abstract
Spinal cord injury (SCI) is a traumatic condition that results in impaired motor and sensory function. Ferroptosis is one of the main causes of neural cell death and loss of neurological function in the spinal cord, and ferroptosis inhibitors are effective in reducing inflammation and repairing SCI. Although human umbilical cord mesenchymal stem cells (Huc-MSCs) can ameliorate inflammatory microenvironments and promote neural regeneration in SCI, their efficacy is greatly limited by the local microenvironment after SCI. Therefore, in this study, we constructed a drug-release nanoparticle system with synergistic Huc-MSCs and ferroptosis inhibitor, in which we anchored Huc-MSCs by a Tz-A6 peptide based on the CD44-targeting sequence, and combined with the reactive oxygen species (ROS)-responsive drug nanocarrier mPEG-b-Lys-BECI-TCO at the other end for SCI repair. Meanwhile, we also modified the classic ferroptosis inhibitor Ferrostatin-1 (Fer-1) and synthesized a new prodrug Feborastatin-1 (Feb-1). The results showed that this treatment regimen significantly inhibited the ferroptosis and inflammatory response after SCI, and promoted the recovery of neurological function in rats with SCI. This study developed a combination therapy for the treatment of SCI and also provides a new strategy for the construction of a drug-coordinated cell therapy system.
Source: openalex_inverted_index · Quality: baseline
Research context
OpenAlex topics: Extracellular vesicles in disease · MicroRNA in disease regulation · Circular RNAs in diseases
SciVX discovery tags are terminology-based. OpenAlex topics are source-provided classifications.
References (78)
Show source-provided references
1. GBD 2016 Neurology Collaborators, Global, regional, and national burden of neurological disorders, 1990-2016: a systematic analysis for the Global Burden of Disease Study 2016, Lancet Neurol. 18 (5) (2019) 459–480.
2. The influence of timing of surgical decompression for acute spinal cord injury: a pooled analysis of individual patient data10.1016/S1474-4422(20)30406-3 ↗
3. A randomized, controlled trial of methylprednisolone or naloxone in the treatment of acute spinal-cord injury. Results of the Second National Acute Spinal Cord Injury Study10.1056/NEJM199005173222001 ↗
4. The translational landscape in spinal cord injury: focus on neuroplasticity and regeneration10.1038/s41582-019-0280-3 ↗
5. Biomaterials reinforced MSCs transplantation for spinal cord injury repair10.1016/j.ajps.2021.03.003 ↗
6. Current options for drug delivery to the spinal cord10.1517/17425247.2013.751372 ↗
7. Current options for cell therapy in spinal cord injury10.1016/j.molmed.2017.07.005 ↗
8. Saad Neuroprotection and immunomodulation by xenografted human mesenchymal stem cells following spinal cord ventral root avulsion10.1038/srep16167 ↗
9. 3D spheroids of human placenta-derived mesenchymal stem cells attenuate spinal cord injury in mice10.1038/s41419-021-04398-w ↗
10. Marrow stromal cells form guiding strands in the injured spinal cord and promote recovery10.1073/pnas.042678299 ↗
11. Nanomedicine therapeutic approaches to overcome cancer drug resistance10.1016/j.addr.2013.09.019 ↗
12. Biopharmaceutics Combination Therapy Using Nanomaterials and Stem Cells to Treat Spinal Cord Injuries10.1016/j.ejpb.2022.07.004 ↗
13. Engineering of M2 Macrophages‐Derived Exosomes via Click Chemistry for Spinal Cord Injury Repair10.1002/adhm.202203391 ↗
14. Bioorthogonal chemistry mediated cell engineering for advanced cell and cell-derived vesicle therapies: principles, progresses, and remaining challenges10.1016/j.cej.2023.148120 ↗
15. Engineered extracellular vesicles for delivery of siRNA promoting targeted repair of traumatic spinal cord injury
16. Mesenchymal stem cell-based drug delivery strategy: from cells to biomimetic10.1016/j.jconrel.2018.12.019 ↗
17. Human-induced neural and mesenchymal stem cell therapy combined with a curcumin nanoconjugate as a spinal cord injury treatment10.3390/ijms22115966 ↗
18. Bari Homing of mesenchymal stem cells: mechanistic or stochastic? Implications for targeted delivery in arthritis10.1093/rheumatology/keu377 ↗
19. Mesenchymal stem cells avoid allogeneic rejection10.1186/1476-9255-2-8 ↗
20. A new three dimensional biomimetic hydrogel to deliver factors secreted by human mesenchymal stem cells in spinal cord injury10.1016/j.biomaterials.2015.10.024 ↗
21. A nanodisc-paved biobridge facilitates stem cell membrane fusogenicity for intracerebral shuttling and bystander effects10.1002/adma.202302367 ↗
22. 3D micropattern force triggers YAP nuclear entry by transport across nuclear pores and modulates stem cells paracrine10.1093/nsr/nwad165 ↗
23. MSC based gene delivery methods and strategies improve the therapeutic efficacy of neurological diseases
24. Deferoxamine promotes recovery of traumatic spinal cord injury by inhibiting ferroptosis10.4103/1673-5374.245480 ↗
25. Different ways to die: cell death pathways and their association with spinal cord injury10.14245/ns.2244976.488 ↗
26. Ferroptosis inhibition protects vascular endothelial cells and maintains integrity of the blood-spinal cord barrier after spinal cord injury10.4103/1673-5374.371377 ↗
27. Ferroptosis is a new therapeutic target for spinal cord injury10.3389/fnins.2023.1136143 ↗
28. Ferrostatin-1 alleviates angiotensin II (Ang II)- induced inflammation and ferroptosis in astrocytes10.1016/j.intimp.2020.107179 ↗
29. Ferrostatin-1 protects HT-22 cells from oxidative toxicity10.4103/1673-5374.266060 ↗
30. Novel ferroptosis inhibitors with improved potency and ADME properties10.1021/acs.jmedchem.5b01641 ↗
31. Click chemistry-conjugated protein-drug micelles with anti-ferroptotic and anti-inflammatory properties promote regeneration in spinal cord injury10.1016/j.cej.2021.132118 ↗
32. Magnetotactic bacteria‐derived Mms6 gene helps M2 macrophages to form magnetic bio‐nanoparticles to prevent ferroptosis and promote locomotor functional recovery after spinal cord injury in mice10.1002/adfm.202305325 ↗
33. Nanoparticles disrupt the PD-1/PD-L1 pathway for efficient cancer immunotherapy10.1002/adma.201905751 ↗
34. Controlled delivery of a neurotransmitter-agonist conjugate for functional recovery after severe spinal cord injury10.1038/s41565-023-01416-0 ↗
35. Minimal criteria for defining multipotent mesenchymal stromal cells. The International Society for Cellular Therapy position statement10.1080/14653240600855905 ↗
36. A sensitive and reliable locomotor rating scale for open field testing in rats10.1089/neu.1995.12.1 ↗
37. Nonresonant powering of injectable nanoelectrodes enables wireless deep brain stimulation in freely moving mice10.1126/sciadv.abc4189 ↗
38. Autologous exosome facilitates load and target delivery of bioactive peptides to repair spinal cord injury
39. Macrophage extracellular traps exacerbate secondary spinal cord injury by modulating macrophage/microglia polarization via LL37/P2X7R/NF-κB signaling pathway10.1155/2022/9197940 ↗
40. Trans-cyclooctene-functionalized PeptoBrushes with improved reaction kinetics of the tetrazine ligation for pretargeted nuclear imaging10.1021/acsnano.9b06905 ↗
41. Amplifying nanoparticle targeting performance to tumor via diels–alder cycloaddition10.1002/adfm.201707596 ↗
42. Dye-sensitized core/active shell upconversion nanoparticles for optogenetics and bioimaging applications10.1021/acsnano.5b06383 ↗
43. A. Elaissari Nanoprecipitation process: from encapsulation to drug delivery10.1016/j.ijpharm.2017.08.064 ↗
44. Nanodrug with ROS and pH dual-sensitivity ameliorates liver fibrosis via multicellular regulation10.1002/advs.201903138 ↗
45. Microenvironment remodeling micelles for alzheimer's disease therapy by early modulation of activated microglia
46. A6 peptide-tagged, ultra-small and reduction-sensitive polymersomal vincristine sulfate as a smart and specific treatment for CD44+ acute myeloid leukemia10.1016/j.jconrel.2020.10.005 ↗
47. CD44-Specific A6 short peptide boosts targetability and anticancer efficacy of polymersomal epirubicin to orthotopic human multiple myeloma10.1002/adma.201904742 ↗
48. Drug-like ferroptosis inhibitors with in vivo efficacy10.1021/acs.jmedchem.8b01299 ↗
49. Photoactivation of boronic acid prodrugs via a phenyl radical mechanism: iridium(III) anticancer complex as an example10.1021/jacs.3c00254 ↗
50. Nrf2-Mediated ferroptosis inhibition exerts a protective effect on acute-on-chronic liver failure10.1155/2022/4505513 ↗
51. Ferroptosis: an iron-dependent form of nonapoptotic cell death10.1016/j.cell.2012.03.042 ↗
52. Selenium utilization by GPX4 is required to prevent hydroperoxide-induced ferroptosis10.1016/j.cell.2017.11.048 ↗
53. Lipid peroxidation-dependent cell death regulated by GPx4 and ferroptosis
54. Nanoengineered mesenchymal stem cell therapy for pulmonary fibrosis in young and aged mice10.1126/sciadv.adg5358 ↗
55. Microenvironment imbalance of spinal cord injury10.1177/0963689718755778 ↗
56. Adipose mesenchymal stem cell transplantation alleviates spinal cord injury-induced neuroinflammation partly by suppressing the Jagged1/Notch pathway10.1186/s13287-020-01724-5 ↗
57. Scarring after spinal cord injury: therapeutic roles of MSCs on inflammation and glial scar10.3389/fimmu.2021.751021 ↗
58. Ferrostatin-1 alleviates lipopolysaccharide-induced acute lung injury via inhibiting ferroptosis10.1186/s11658-020-00205-0 ↗
59. Carrier-free nanodrug based on Co-assembly of methylprednisolone dimer and rutin for combined treatment of spinal cord injury10.1021/acsnano.3c00360 ↗
60. A shear-thinning, ROS-scavenging hydrogel combined with dental pulp stem cells promotes spinal cord repair by inhibiting ferroptosis
61. A reactive oxygen species-responsive hydrogel encapsulated with bone marrow derived stem cells promotes repair and regeneration of spinal cord injury
62. A. Vercelli Human mesenchymal stromal cell transplantation modulates neuroinflammatory milieu in a mouse model of amyotrophic lateral sclerosis10.1016/j.jcyt.2014.02.003 ↗
63. The cell repair research of spinal cord injury: a review of cell transplantation to treat spinal cord injury10.26599/JNR.2019.9040011 ↗
64. Biological responses and mechanisms of human bone marrow mesenchymal stem cells to Zn and Mg biomaterials10.1021/acsami.7b06654 ↗
65. In vitro evaluation of MgSr and MgCaSr alloys via direct culture with bone marrow derived mesenchymal stem cells10.1016/j.actbio.2018.03.049 ↗
66. Heterogeneous DNA hydrogel loaded with Apt02 modified tetrahedral framework nucleic acid accelerated critical-size bone defect repair
67. Recent advances in the combination of cellular therapy with stem cells and nanoparticles after a spinal cord injury10.3389/fneur.2023.1127878 ↗
68. Encapsulation of nano-bortezomib in apoptotic stem cell-derived vesicles for the treatment of multiple myeloma
69. Stem cells for neurological disorders10.1002/advs.202002944 ↗
70. A factor-free hydrogel with ROS scavenging and responsive degradation for enhanced diabetic bone healing
71. Exosome-based bone-targeting drug delivery alleviates impaired osteoblastic bone formation and bone loss in inflammatory bowel diseases
72. ROS-scavenging hydrogels synergize with neural stem cells to enhance spinal cord injury repair via regulating microenvironment and facilitating nerve regeneration10.1002/adhm.202300123 ↗
73. Early modulation of pro-inflammatory microglia by minocycline loaded nanoparticles confers long lasting protection after spinal cord injury10.1016/j.biomaterials.2015.10.015 ↗
74. A backpack-based myeloid cell therapy for multiple sclerosis10.1073/pnas.2221535120 ↗
75. Surface-tethered ROS-responsive micelle backpacks for boosting mesenchymal stem cell vitality and modulating inflammation in ischemic stroke treatment10.1016/j.jconrel.2023.08.039 ↗
76. CD44-targeting hydrophobic phosphorylated gemcitabine prodrug nanotherapeutics augment lung cancer therapy10.1016/j.actbio.2022.04.016 ↗
77. Intrinsic and extrinsic limitations to the design and optimization of inhibitors of lipid peroxidation and associated cell death10.1021/jacs.2c05252 ↗
78. Poly(2-oxazoline) - ferrostatin-1 drug conjugates inhibit ferroptotic cell death10.1016/j.jconrel.2022.08.004 ↗